Business Context and Reporting Period
Company: The Cooper Companies, Inc.
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Three months ended January 31, 2003 (First Quarter of Fiscal 2003)
Business Overview: The Company operates through two primary segments: CooperVision (CVI), which markets specialty contact lenses, and CooperSurgical (CSI), which markets medical devices and surgical instruments for women's healthcare.
Key Financial Metrics
| Metric (in thousands) | Q1 2003 | Q1 2002 |
|---|---|---|
| Net Sales | $94,014 | $58,112 |
| Gross Profit | $59,367 | $37,485 |
| Gross Margin | 63.1% | 64.5% |
| Operating Income | $19,819 | $13,107 |
| Net Income | $13,855 | $9,405 |
| Diluted EPS | $0.44 | $0.30 |
| Cash from Operations | $3,112 | $4,168 |
| Total Debt | $176,355 | $63,900 (Jan 31, 2002) |
| Cash & Equivalents | $9,054 | $10,255 (Oct 31, 2002) |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 62% to $94.0 million, driven by a 73% increase in CVI sales and a 33% increase in CSI sales. Growth was significantly aided by the acquisition of Biocompatibles Eye Care, Inc. (completed Feb 2002).
- Profitability: Operating income rose 51% to $19.8 million. Net income increased 47% to $13.9 million.
- Margins: Gross margin declined slightly to 63% from 65%, attributed to the strengthening of the British pound (increasing manufacturing costs for UK-based CVI operations) and lower-margin sales to a Japanese distributor.
- Debt Levels: Total debt increased substantially to $176.4 million from $63.9 million a year prior, primarily due to borrowings used to fund acquisitions and retire higher-interest promissory notes.
- Working Capital: Working capital improved to $111.6 million from $72.2 million, though Days Sales Outstanding (DSO) increased to 79 days due to currency impacts and system integration issues.
Outlook, Risks, and Management Commentary
- Guidance & Outlook: Management expects R&D expenses to increase by $1.5 million to $2.0 million in fiscal 2003. CSI gross margins are expected to return to the 53% range by the end of the second quarter as new operations integrate. The effective tax rate is estimated at 25% for the full fiscal year.
- Liquidity: The Company maintains $9.1 million in cash and $52.9 million available under its KeyBank line of credit. Management believes these resources are sufficient to fund operations, capital expenditures, dividends, and smaller acquisitions.
- Risks & Contingencies:
- Litigation: A trademark infringement lawsuit filed by Dioptics Medical Products, Inc. regarding the "CV Encore" lenses is set for trial in June 2003. The Company recorded a $500,000 provision for a potential settlement.
- Currency: Significant exposure to foreign exchange fluctuations, particularly the British pound, which impacts both revenue translation and manufacturing costs.
- Integration: Risks associated with integrating recent acquisitions (Biocompatibles, Norland Medical Systems, Ackrad Laboratories).
- Unusual Items: Other income included a $1.1 million gain from foreign exchange transactions due to the strengthening pound, offset by a $500,000 legal settlement provision.
Investor Verification Checklist
- Acquisition Impact: Verify the organic growth rate of CVI and CSI by excluding revenue from the Biocompatibles acquisition to assess underlying business momentum.
- Currency Sensitivity: Monitor the impact of the British pound on future gross margins, as a significant portion of CVI manufacturing is UK-based.
- Debt Servicing: Review the interest expense trajectory given the increase in total debt to $176.4 million and the shift to variable-rate debt (KeyBank line of credit).
- Legal Exposure: Track the status of the Dioptics trademark litigation and potential additional settlement costs beyond the $500,000 provision.
- DSO Trends: Monitor Days Sales Outstanding, which rose to 79 days, to ensure collection efforts improve as system integration issues are resolved.